Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Evkeeza evinacumab Homozygous familial hypercholesterolemia (HoFH) Reimburse with clinical criteria and/or conditions Complete
Evra Norgelestromin/ethinyl estradiol Contraceptive, patch Do not list Complete
Evrysdi risdiplam Spinal muscular atrophy Reimburse with clinical criteria and/or conditions Complete
Exelon Patch Rivastigmine Dementia (Alzheimer's type) Do not list Complete
Exjade Deferasirox Iron overload List with clinical criteria and/or conditions Complete
Eylea Aflibercept Macular degeneration, age-related List with criteria/condition Complete
Eylea Aflibercept Macular edema, branch retinal vein occlusion Reimburse with clinical criteria and/or conditions Complete
Eylea Aflibercept Macular edema, diabetic List with clinical criteria and/or conditions Complete
Eylea Aflibercept Macular edema, central retinal vein occlusion List with clinical criteria and/or conditions Complete
Eylea HD aflibercept 8mg/0.07mL macular degeneration, age related Reimburse with clinical criteria and/or conditions Active